Lymphomatoid papulosis (LyP) type E is a recently described variant characterized by the occurrence of large necrotic eschar-like lesions displaying microscopically angioinvasive and angiodestructive infiltrates of CD30+ lymphocytes, frequently coexpressing CD8. Rare cases of LyP type E with a CD56+ immunophenotype have been described. Herein, we describe a 36-year-old woman with LyP type E, characterized by purpura-like lesions on her left ankle. Initially, she presented with left ankle swelling, petechiae and ecchymosis, and rapidly developing necrotic papules, all of which resolved spontaneously over a period of a few months without intentional therapy. Biopsy revealed CD30 and CD56 positive atypical cell infiltrates with marked angiocentricity and angiodestruction. Awareness of this rare LyP variant and its correct recognition, even if the clinical presentation is unusual, is important to avoid aggressive treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cup.13472 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The protein tyrosine phosphatase Lyp/PTPN22 drives TNFα-induced priming of superoxide anions production by neutrophils and arthritis.
Free Radic Biol Med
December 2024
INSERM-U1149, CNRS-ERL8252, Université de Paris-Cité, Centre de Recherche sur l'Inflammation, Laboratoire d'Excellence Inflamex, DHU FIRE, Faculté de Médecine, Site Xavier Bichat, Paris, France. Electronic address:
Neutrophils are essential for host defense against infections, but they also play a key role in acute and chronic inflammation. The protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene encodes the lymphoid-specific tyrosine phosphatase (Lyp) and a genetic single-nucleotide polymorphism of PTPN22 rs2476601 (R620W) has been associated with several human autoimmune diseases, including rheumatoid arthritis (RA). Here, we investigated the role of Lyp in TNFα-induced priming of neutrophil ROS production and in the development of arthritis using new selective Lyp inhibitors.
View Article and Find Full Text PDFStructure-activity relationship studies and design of a PTPN22 inhibitor with enhanced isozyme selectivity and cellular efficacy.
Eur J Med Chem
December 2024
Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA; James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA; Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, USA; Institute for Cancer Research, Purdue University, West Lafayette, IN 47907, USA. Electronic address:
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) lies downstream of the T cell receptor (TCR) and attenuates T cell signaling by dephosphorylating key effector proteins such as LCK, Zap70, and the intracellular region of the TCR. Recent evidence implicates PTPN22 as an exciting target for enabling immunotherapeutic efficacy against cancer. We carried out structural optimization of a benzofuran salicylic acid-based orthosteric PTPN22 inhibitor 8b, using a combination of crystal structure analysis, synthesis, matched molecular pairs analysis, and biochemical and cell-based assays.
View Article and Find Full Text PDFLYP regulates SLP76 and other adaptor proteins in T cells.
Biol Res
September 2024
Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM), CSIC-Universidad de Valladolid, c/ Sanz y Forés 3, 47003, Valladolid, Spain.
Background: The LYP tyrosine phosphatase presents a SNP (1858C > T) that increases the risk of developing autoimmune diseases such as type I diabetes and arthritis. It remains unclear how this SNP affects LYP function and promotes the development of these diseases. The scarce information about LYP substrates is in part responsible for the poor understanding of LYP function.
View Article and Find Full Text PDFLymphomatoid Papulosis Type D in a Mestizo-Ancestry Man.
Am J Dermatopathol
November 2024
Service of Dermatology, Hospital General de México "Dr. Eduardo Liceaga, " S.S./School of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico; and.
Article Synopsis
- * Type D LyP is characterized by the presence of abnormal CD8+ and CD30+ lymphocytes, which presents diagnostic challenges due to similarities with more aggressive forms of skin lymphomas.
- * A clinical case of a 22-year-old man with type D LyP demonstrated a favorable prognosis, highlighting the need to share findings related to this condition, especially among mestizo or Latin-American patients, as there are few published cases in this demographic.*
Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas.
Cancers (Basel)
September 2024
Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA.
Article Synopsis
- The text discusses the classification of Cutaneous T-cell Lymphomas (CTCL), highlighting the prevalence of CD4+ T-helper cell variants and a spectrum of CD8+ variants with various clinical and histological features.
- CD8 and cytotoxic molecules can be identified through immunohistochemical staining, but their presence alone is not enough for diagnosis or determining prognosis.
- The review covers specific CTCL subtypes that express CD8 positivity, including mycosis fungoides, lymphomatoid papulosis, and aggressive forms, underscoring the importance of combining clinical, histologic, and immunohistochemical data for accurate diagnosis and treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!